Table 3.
Genotypic characterization of 145 NG positive samples.
| Mono drug resistance | Double drug resistance | Triple drug resistance | |||||
|---|---|---|---|---|---|---|---|
| PPNG | TRNG | CRNG | PPNG/TRNG | PPNG/ CRNG | TRNG/CRNG | PPNG/TRNG/CRNG | |
|
| |||||||
| PPNG | |||||||
| Africa | - | - | - | - | - | - | - |
| Asia | - | - | - | 2 | 3 | - | 5 |
| Toronto | 1 | - | - | 2 | 7 | - | 3 |
| Toronto/Asia | - | - | - | - | 3 | - | 10 |
| Total | 1 | - | - | 4 | 13 | - | 18 |
| TRNG | |||||||
| America | - | 13 | - | 4 | - | 30 | 17 |
| Dutch | - | 1 | - | - | - | 3 | 1 |
| Total | - | 14 | - | 4 | - | 33 | 18 |
| CRNG | |||||||
| Mutation S91 GyrA | - | - | 52 | - | 13 | 33 | 18 |
PPNG, penicillinase-producing N. gonorrhoeae (plasmid-mediated); TRNG, tetracycline resistant N. gonorrhoeae (plasmid-mediated); CRNG: ciprofloxacin-resistant N. gonorrhoeae.